Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04670679 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Erasca.
- Active
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 14
- Study locations
NCT04670679: Active Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Erasca.
NCT04670679 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Erasca. The registered enrollment target is 200 participants, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower). The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04670679, a Phase 1 study of Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Erasca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 14
- Study locations
Study Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
Primary Outcome
Based on toxicities observed
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cetuximab
- DRUG ERAS-601
Study Locations (14)
Texas
- Mary Crowley Cancer Research - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Sarah Cannon Research Institute (Florida Cancer Specialists) - Sarasota
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University - St Louis
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
What the registry record for NCT04670679 still lists
NCT04670679 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04670679 lists 14 locations in 13 states (Texas, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT04670679 about?
NCT04670679 is a clinical study titled "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors". * To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ...
What is the current status of trial NCT04670679?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-12-15. Estimated completion is 2026-02.
What conditions does trial NCT04670679 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT04670679?
The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), ERAS-601 (DRUG).
Who is sponsoring clinical trial NCT04670679?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04670679 being conducted?
This trial has 14 study locations across Alabama, Florida, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04670679's enrollment target sits among peer trials
200 9th of 19 higher than 10 of 19 other Advanced or Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced or Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI